Search

Your search keyword '"Röckmann, Heike"' showing total 133 results
Start Over Author "Röckmann, Heike"
133 results on '"Röckmann, Heike"'

1. Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation

Author

Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Soegiharto, Reineke, Alizadeh Aghdam, Mehran, Sørensen, Jennifer Astrup, van Lindonk, Esmee, Bulut Demir, Ferhan, Porras, Nasser Mohammad, Matsuo, Yoshimi, Kiefer, Lea, Knulst, André C, Maurer, Marcus, Ritchie, Carla, Rudenko, Michael, Kocatürk, Emek, Criado, Roberta F J, Gregoriou, Stamatis, Bobylev, Tatjana, Kleinheinz, Andreas, Takahagi, Shunsuke, Hide, Michihiro, Giménez-Arnau, Ana M, Salman, Andaç, Kara, Rabia O, Sevimli Dikicier, Bahar, van Doorn, Martijn B A, Thomsen, Simon F, van den Reek, Juul M P A, Röckmann, Heike, Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Soegiharto, Reineke, Alizadeh Aghdam, Mehran, Sørensen, Jennifer Astrup, van Lindonk, Esmee, Bulut Demir, Ferhan, Porras, Nasser Mohammad, Matsuo, Yoshimi, Kiefer, Lea, Knulst, André C, Maurer, Marcus, Ritchie, Carla, Rudenko, Michael, Kocatürk, Emek, Criado, Roberta F J, Gregoriou, Stamatis, Bobylev, Tatjana, Kleinheinz, Andreas, Takahagi, Shunsuke, Hide, Michihiro, Giménez-Arnau, Ana M, Salman, Andaç, Kara, Rabia O, Sevimli Dikicier, Bahar, van Doorn, Martijn B A, Thomsen, Simon F, van den Reek, Juul M P A, and Röckmann, Heike

Published
2024

2. Prevalence of chronic urticaria and healthcare usage of patients with the condition in primary care: A Population-Based Study in The Netherlands

Author

MS Dermatologie/Allergologie, Infection & Immunity, Soegiharto, Reineke, Westmeijer, Mike, Boekema-Bakker, Nicole, Groenewegen, Irene A M, Knulst, André C, van den Reek, Juul M P A, Röckmann, Heike, MS Dermatologie/Allergologie, Infection & Immunity, Soegiharto, Reineke, Westmeijer, Mike, Boekema-Bakker, Nicole, Groenewegen, Irene A M, Knulst, André C, van den Reek, Juul M P A, and Röckmann, Heike

Published
2024

3. Two cases with generalised bullous cutaneous reactions after COVID-19 mRNA vaccine Moderna (Spikevax®) and Pfizer–BioNTech (Comirnaty®)

Author

MS Dermatologie/Allergologie, Infection & Immunity, Pathologie Pathologen staf, Cancer, Rinnooy Kan, Charlotte E., Röckmann, Heike, van Dijk, Marijke R., Ramsaransing, Tanuja, Reubsaet, Lieke L., Peters, Elke E.M., Vos, Lydia E., MS Dermatologie/Allergologie, Infection & Immunity, Pathologie Pathologen staf, Cancer, Rinnooy Kan, Charlotte E., Röckmann, Heike, van Dijk, Marijke R., Ramsaransing, Tanuja, Reubsaet, Lieke L., Peters, Elke E.M., and Vos, Lydia E.

Published
2024

4. Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation

Author

Soegiharto, Reineke, Alizadeh Aghdam, Mehran, Sørensen, Jennifer Astrup, van Lindonk, Esmee, Bulut Demir, Ferhan, Porras, Nasser Mohammad, Matsuo, Yoshimi, Kiefer, Lea, Knulst, André C., Maurer, Marcus, Ritchie, Carla, Rudenko, Michael, Kocatürk, Emek, Criado, Roberta F. J., Gregoriou, Stamatis, Bobylev, Tatjana, Kleinheinz, Andreas, Takahagi, Shunsuke, Hide, Michihiro, Giménez-Arnau, Ana M., Salman, Andaç, Kara, Rabia O., Sevimli Dikicier, Bahar, van Doorn, Martijn B. A., Thomsen, Simon F., van den Reek, Juul M. P. A., and Röckmann, Heike

Abstract

IMPORTANCE: Treating patients with chronic urticaria using omalizumab has been shown to be safe and effective in randomized clinical trials. Multinational studies on long-term omalizumab performance in chronic urticaria in clinical practice settings are lacking, especially on drug survival. Drug survival, which refers to the length of time that patients are treated with a specific drug, is a comprehensive outcome covering effectiveness, safety, and patient and physician preferences. Furthermore, little is known about the reasons and potential predictors for omalizumab discontinuation. OBJECTIVE: To investigate omalizumab drug survival as well as reasons and potential predictors for discontinuation in a large, diverse population. DESIGN, SETTING, AND PARTICIPANTS: This international multicenter cohort study was conducted at 14 Urticaria Centers of Reference and Excellence in 10 countries, including all patients with chronic urticaria from these centers who were ever treated with omalizumab. MAIN OUTCOMES AND MEASURES: Drug survival analysis was performed to assess time to discontinuation. Patient characteristics and treatment protocols were investigated by Cox regression analysis to identify potential predictors for omalizumab discontinuation. RESULTS: In 2325 patients with chronic urticaria who started omalizumab between June 2009 and July 2022, the mean (SD) age of the cohort was 42 (6) years, and 1650 participants (71%) were female. Overall omalizumab survival rates decreased from 76% to 39% after 1 to 7 years, respectively (median survival time, 3.3 [95 % CI, 2.9-4.0] years), primarily due to discontinuation from well-controlled disease in 576 patients (65%). Ineffectiveness and adverse effects were reasons for discontinuation in a far smaller proportion of patients, totaling 164 patients (18%) and 31 patients (4%), respectively. Fast treatment response was associated with higher rates of omalizumab discontinuation due to well-controlled disease (hazard ratio, 1.45 [95% CI, 1.20-1.75]), and disease duration of more than 2 years was associated with lower rates of discontinuation due to well-controlled disease (HR, 0.81 [95% CI, 0.67-0.98]). Immunosuppressive cotreatment at the start of omalizumab and autoimmune disease was associated with a higher risk for discontinuation due to ineffectiveness (HR, 1.65 [95% CI, 1.12-2.42]). The presence of spontaneous wheals (HR, 0.62 [95% CI, 0.41-0.93]) and access to higher dosages (HR, 0.40 [95% CI, 0.27-0.58) were both associated with a lower risk for discontinuation of omalizumab due to ineffectiveness. CONCLUSION AND RELEVANCE: This multinational omalizumab drug survival cohort study demonstrated that treatment of chronic urticaria with omalizumab in a clinical setting is effective and safe, and well-controlled disease is the main reason for treatment discontinuation. These findings on omalizumab drug survival rates and reasons and potential predictors for discontinuation may guide patients and physicians in clinical decision-making and expectation management. These results may call for the identification of biomarkers for chronic urticaria remission in complete responders to omalizumab treatment.

Published
2024
Full Text
View/download PDF

11. Age and fast initial response predict omalizumab retreatment in chronic urticaria

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, VS-DIGD, Meertens, Michelle A.J., Luijf, Teddy, van Lindonk, Esmee A.M., Soegiharto, Reineke, Assil, Salma, Alizadeh Aghdam, Mehran, Kentie, Petra A., Knulst, Andre C., van Doorn, Martijn B.A., Röckmann, Heike, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, VS-DIGD, Meertens, Michelle A.J., Luijf, Teddy, van Lindonk, Esmee A.M., Soegiharto, Reineke, Assil, Salma, Alizadeh Aghdam, Mehran, Kentie, Petra A., Knulst, Andre C., van Doorn, Martijn B.A., and Röckmann, Heike

Published
2023

12. Age and fast initial response predict omalizumab retreatment in chronic urticaria

Author

Meertens, Michelle A.J., Luijf, Teddy, van Lindonk, Esmee A.M., Soegiharto, Reineke, Assil, Salma, Alizadeh Aghdam, Mehran, Kentie, Petra A., Knulst, Andre C., van Doorn, Martijn B.A., Röckmann, Heike, Meertens, Michelle A.J., Luijf, Teddy, van Lindonk, Esmee A.M., Soegiharto, Reineke, Assil, Salma, Alizadeh Aghdam, Mehran, Kentie, Petra A., Knulst, Andre C., van Doorn, Martijn B.A., and Röckmann, Heike

Published
2023

17. Prevalence of chronic urticaria and healthcare usage of patients with the condition in primary care: a population-based study in the Netherlands.

Author

Soegiharto, Reineke, Westmeijer, Mike, Boekema-Bakker, Nicole, Groenewegen, Irene A M, Knulst, André C, Reek, Juul M P A van den, and Röckmann, Heike

Subjects
URTICARIA, PRIMARY care, INFORMED consent (Medical law), MEDICAL care
Abstract

This article presents a population-based study conducted in the Netherlands to investigate the prevalence and healthcare usage of patients with chronic urticaria (CU) in primary care. The study analyzed healthcare usage data from 200 general practitioners (GPs) and found that the annual point prevalence of CU ranged from 0.48% to 0.30% between 2010 and 2018. The median follow-up duration for CU patients was 1.5 years, and the study revealed relatively modest healthcare usage for CU in the general population. These findings provide valuable insights for counseling new patients with CU in both primary and specialist care settings. [Extracted from the article]

Published
2024
Full Text
View/download PDF

18. Allergies and COVID-19 vaccines:An ENDA/EAACI Position paper

Author

Barbaud, Annick, Garvey, Lene Heise, Arcolaci, Alessandra, Brockow, Knut, Mori, Francesca, Mayorga, Cristobalina, Bonadonna, Patrizia, Atanaskovic-Markovic, Marina, Moral, Luis, Zanoni, Giovanna, Pagani, Mauro, Soria, Angèle, Jošt, Maja, Caubet, Jean-Christoph, Carmo, Abreu, Mona, Al Ahmad, Alvarez-Perea, Alberto, Bavbek, Sevim, Benedetta, Biagioni, Bilo, M Beatrice, Blanca-López, Natalia, Bogas, Herrera Gádor, Buonomo, Alessandro, Calogiuri, Gianfranco, Carli, Giulia, Cernadas, Josefina, Cortellini, Gabriele, Celik, Gülfem, Demir, Semra, Doña, Inmaculada, Dursun, Adile Berna, Eberlein, Bernadette, Faria, Emilia, Fernandes, Bryan, Garcez, Tomaz, Garcia-Nunez, Ignacio, Gawlik, Radoslaw, Gelincik, Asli, Gomes, Eva, Gooi, Jimmy H. C., Grosber, Martine, Gülen, Theo, Hacard, Florence, Hoarau, Cyrille, Janson, Christer, Johnston, Sebastian L, Joerg, Lukas, Kepil Özdemir, Seçil, Klimek, Ludger, Košnik, Mitja, Kowalski, Marek L, Kuyucu, Semanur, Kvedariene, Violeta, Laguna, Jose Julio, Lombardo, Carla, Marinho, Susana, Merk, Hans, Meucci, Elisa, Morisset, Martine, Munoz-Cano, Rosa, Murzilli, Francesco, Nakonechna, Alla, Popescu, Florin Dan, Porebski, Grzegorz, Radice, Anna, Regateiro, Frederico S., Röckmann, Heike, Romano, Antonino, Sargur, Ravishankar, Sastre, Joaquin, Hofmeier, Kathrin Scherer, Sedláčková, Lenka, Sobotkova, Marta, Terreehorst, Ingrid, Treudler, Regina, Walusiak-Skorupa, Jolanta, Wedi, Bettina, Wöhrl, Stefan, Zidarn, Mihael, Zuberbier, Torsten, Agache, Ioana, Torres, Maria J., Barbaud, Annick, Garvey, Lene Heise, Arcolaci, Alessandra, Brockow, Knut, Mori, Francesca, Mayorga, Cristobalina, Bonadonna, Patrizia, Atanaskovic-Markovic, Marina, Moral, Luis, Zanoni, Giovanna, Pagani, Mauro, Soria, Angèle, Jošt, Maja, Caubet, Jean-Christoph, Carmo, Abreu, Mona, Al Ahmad, Alvarez-Perea, Alberto, Bavbek, Sevim, Benedetta, Biagioni, Bilo, M Beatrice, Blanca-López, Natalia, Bogas, Herrera Gádor, Buonomo, Alessandro, Calogiuri, Gianfranco, Carli, Giulia, Cernadas, Josefina, Cortellini, Gabriele, Celik, Gülfem, Demir, Semra, Doña, Inmaculada, Dursun, Adile Berna, Eberlein, Bernadette, Faria, Emilia, Fernandes, Bryan, Garcez, Tomaz, Garcia-Nunez, Ignacio, Gawlik, Radoslaw, Gelincik, Asli, Gomes, Eva, Gooi, Jimmy H. C., Grosber, Martine, Gülen, Theo, Hacard, Florence, Hoarau, Cyrille, Janson, Christer, Johnston, Sebastian L, Joerg, Lukas, Kepil Özdemir, Seçil, Klimek, Ludger, Košnik, Mitja, Kowalski, Marek L, Kuyucu, Semanur, Kvedariene, Violeta, Laguna, Jose Julio, Lombardo, Carla, Marinho, Susana, Merk, Hans, Meucci, Elisa, Morisset, Martine, Munoz-Cano, Rosa, Murzilli, Francesco, Nakonechna, Alla, Popescu, Florin Dan, Porebski, Grzegorz, Radice, Anna, Regateiro, Frederico S., Röckmann, Heike, Romano, Antonino, Sargur, Ravishankar, Sastre, Joaquin, Hofmeier, Kathrin Scherer, Sedláčková, Lenka, Sobotkova, Marta, Terreehorst, Ingrid, Treudler, Regina, Walusiak-Skorupa, Jolanta, Wedi, Bettina, Wöhrl, Stefan, Zidarn, Mihael, Zuberbier, Torsten, Agache, Ioana, and Torres, Maria J.

Abstract

Background: Anaphylaxis, which is rare, has been reported after COVID-19 vaccination, but its management is not standardized. Method: Members of the European Network for Drug Allergy and the European Academy of Allergy and Clinical Immunology interested in drug allergy participated in an online questionnaire on pre-vaccination screening and management of allergic reactions to COVID-19 vaccines, and literature was analysed. Results: No death due to anaphylaxis to COVID-19 vaccines has been confirmed in scientific literature. Potential allergens, polyethylene glycol (PEG), polysorbate and tromethamine are excipients. The authors propose allergy evaluation of persons with the following histories: 1—anaphylaxis to injectable drug or vaccine containing PEG or derivatives; 2—anaphylaxis to oral/topical PEG containing products; 3—recurrent anaphylaxis of unknown cause; 4—suspected or confirmed allergy to any mRNA vaccine; and 5—confirmed allergy to PEG or derivatives. We recommend a prick-to-prick skin test with the left-over solution in the suspected vaccine vial to avoid waste. Prick test panel should include PEG 4000 or 3500, PEG 2000 and polysorbate 80. The value of in vitro test is arguable. Conclusions: These recommendations will lead to a better knowledge of the management and mechanisms involved in anaphylaxis to COVID-19 vaccines and enable more people with history of allergy to be vaccinated.

Published
2022

19. Recombinant human C1 esterase inhibitor as prophylactic treatment in idiopathic non-histaminergic angioedema

Author

CTI, Unit Opleiding Dermatologie, Infection & Immunity, MS Dermatologie/Allergologie, CDL Staf Research, Circulatory Health, CDL Cluster Onderzoek en Onderwijs, Alizadeh Aghdam, Mehran, Hofman, Zonne L.M., Meertens, Michelle, Lebens, Ans, Hack, C. Erik, Knulst, André C., Maas, Coen, Röckmann, Heike, CTI, Unit Opleiding Dermatologie, Infection & Immunity, MS Dermatologie/Allergologie, CDL Staf Research, Circulatory Health, CDL Cluster Onderzoek en Onderwijs, Alizadeh Aghdam, Mehran, Hofman, Zonne L.M., Meertens, Michelle, Lebens, Ans, Hack, C. Erik, Knulst, André C., Maas, Coen, and Röckmann, Heike

Published
2022

20. Allergies and COVID‐19 vaccines: An ENDA/EAACI Position paper

Author

Barbaud, Annick, primary, Garvey, Lene Heise, additional, Arcolaci, Alessandra, additional, Brockow, Knut, additional, Mori, Francesca, additional, Mayorga, Cristobalina, additional, Bonadonna, Patrizia, additional, Atanaskovic‐Markovic, Marina, additional, Moral, Luis, additional, Zanoni, Giovanna, additional, Pagani, Mauro, additional, Soria, Angèle, additional, Jošt, Maja, additional, Caubet, Jean‐Christoph, additional, Carmo, Abreu, additional, Mona, Al‐Ahmad, additional, Alvarez‐Perea, Alberto, additional, Bavbek, Sevim, additional, Benedetta, Biagioni, additional, Bilo, M.Beatrice, additional, Blanca‐López, Natalia, additional, Bogas, Herrera Gádor, additional, Buonomo, Alessandro, additional, Calogiuri, Gianfranco, additional, Carli, Giulia, additional, Cernadas, Josefina, additional, Cortellini, Gabriele, additional, Celik, Gülfem, additional, Demir, Semra, additional, Doña, Inmaculada, additional, Dursun, Adile Berna, additional, Eberlein, Bernadette, additional, Faria, Emilia, additional, Fernandes, Bryan, additional, Garcez, Tomaz, additional, Garcia‐Nunez, Ignacio, additional, Gawlik, Radoslaw, additional, Gelincik, Asli, additional, Gomes, Eva, additional, Gooi, Jimmy H. C., additional, Grosber, Martine, additional, Gülen, Theo, additional, Hacard, Florence, additional, Hoarau, Cyrille, additional, Janson, Christer, additional, Johnston, Sebastian L., additional, Joerg, Lukas, additional, Kepil Özdemir, Seçil, additional, Klimek, Ludger, additional, Košnik, Mitja, additional, Kowalski, Marek L., additional, Kuyucu, Semanur, additional, Kvedariene, Violeta, additional, Laguna, Jose Julio, additional, Lombardo, Carla, additional, Marinho, Susana, additional, Merk, Hans, additional, Meucci, Elisa, additional, Morisset, Martine, additional, Munoz‐Cano, Rosa, additional, Murzilli, Francesco, additional, Nakonechna, Alla, additional, Popescu, Florin‐Dan, additional, Porebski, Grzegorz, additional, Radice, Anna, additional, Regateiro, Frederico S., additional, Röckmann, Heike, additional, Romano, Antonino, additional, Sargur, Ravishankar, additional, Sastre, Joaquin, additional, Scherer Hofmeier, Kathrin, additional, Sedláčková, Lenka, additional, Sobotkova, Marta, additional, Terreehorst, Ingrid, additional, Treudler, Regina, additional, Walusiak‐Skorupa, Jolanta, additional, Wedi, Bettina, additional, Wöhrl, Stefan, additional, Zidarn, Mihael, additional, Zuberbier, Torsten, additional, Agache, Ioana, additional, and Torres, Maria J., additional

Published
2022
Full Text
View/download PDF

22. Intervalverlenging bij omalizumab behandeling van patiënten met chronische urticaria

Author

Afdeling Dermatologie/Allergologie, Zorgeenheid Vaatchirurgie Medisch, Infection & Immunity, MS Dermatologie/Allergologie, VS-DIGD, VS-DER, Meertens, M. A.J., Alizadeh Aghdam, M., Pieterse, R. H., Kentie, P. A., Rijken, F., Knulst, A. C., Röckmann, Heike, Afdeling Dermatologie/Allergologie, Zorgeenheid Vaatchirurgie Medisch, Infection & Immunity, MS Dermatologie/Allergologie, VS-DIGD, VS-DER, Meertens, M. A.J., Alizadeh Aghdam, M., Pieterse, R. H., Kentie, P. A., Rijken, F., Knulst, A. C., and Röckmann, Heike

Published
2021

23. Verdenking op allergische reactie op COVID-19 vaccinatie: praktische overwegingen

Author

Afdeling Dermatologie/Allergologie, Zorgeenheid Vaatchirurgie Medisch, VS-DIGD, Infection & Immunity, VS-DER, MS Dermatologie/Allergologie, Meertens, M. A.J., Versluis, A., Knulst, A. C., Röckmann, Heike, Afdeling Dermatologie/Allergologie, Zorgeenheid Vaatchirurgie Medisch, VS-DIGD, Infection & Immunity, VS-DER, MS Dermatologie/Allergologie, Meertens, M. A.J., Versluis, A., Knulst, A. C., and Röckmann, Heike

Published
2021

24. Systemic and local evidence for complement involvement in chronic spontaneous urticaria

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, Afdeling Dermatologie/Allergologie, Pathologie Pathologen staf, Cancer, CTI Research, CDL Patiëntenzorg MI, Alizadeh Aghdam, Mehran, van den Elzen, Mignon, van Os-Medendorp, Harmieke, van Dijk, Marijke R, Knol, Edward F, Knulst, André C, Röckmann, Heike, Otten, Henny G, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, Afdeling Dermatologie/Allergologie, Pathologie Pathologen staf, Cancer, CTI Research, CDL Patiëntenzorg MI, Alizadeh Aghdam, Mehran, van den Elzen, Mignon, van Os-Medendorp, Harmieke, van Dijk, Marijke R, Knol, Edward F, Knulst, André C, Röckmann, Heike, and Otten, Henny G

Published
2021

25. Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients

Author

MS Dermatologie/Allergologie, Infection & Immunity, Dekkers, Coco, Alizadeh Aghdam, Mehran, Graaf, Marlies de, Knulst, André C, Meijer, Yolanda, van den Reek, Juul M P A, Stadermann, Marike B, Röckmann, Heike, MS Dermatologie/Allergologie, Infection & Immunity, Dekkers, Coco, Alizadeh Aghdam, Mehran, Graaf, Marlies de, Knulst, André C, Meijer, Yolanda, van den Reek, Juul M P A, Stadermann, Marike B, and Röckmann, Heike

Published
2021

31. Effective omalizumab interval prolongation in the treatment of chronic urticaria

Author

MS Dermatologie/Allergologie, Infection & Immunity, Poli DER, Alizadeh Aghdam, Mehran, Pieterse, Rianne Henriëtte, Kentie, Petra Adriana, Rijken, Feiko, Knulst, André Cornelis, Röckmann, Heike, MS Dermatologie/Allergologie, Infection & Immunity, Poli DER, Alizadeh Aghdam, Mehran, Pieterse, Rianne Henriëtte, Kentie, Petra Adriana, Rijken, Feiko, Knulst, André Cornelis, and Röckmann, Heike

Published
2020

32. High-dose omalizumab use in patients with chronic spontaneous urticaria

Author

MS Dermatologie/Allergologie, UMC Utrecht, Infection & Immunity, Alizadeh Aghdam, Mehran, van den Broek, Fenne, Rijken, Feiko, Knulst, Andre Cornelis, Röckmann, Heike, MS Dermatologie/Allergologie, UMC Utrecht, Infection & Immunity, Alizadeh Aghdam, Mehran, van den Broek, Fenne, Rijken, Feiko, Knulst, Andre Cornelis, and Röckmann, Heike

Published
2020

40. High occurrence of antihistamine resistance in patients with recurrent idiopathic angioedema

Author

Infection & Immunity, CDL unit HLA, CTI, MS Dermatologie/Allergologie, CDL Staf Research, Hofman, Zonne L.M., Van West, Nikki, Hack, C. Erik, Knulst, André C., Maas, Coen, Röckmann, Heike, Infection & Immunity, CDL unit HLA, CTI, MS Dermatologie/Allergologie, CDL Staf Research, Hofman, Zonne L.M., Van West, Nikki, Hack, C. Erik, Knulst, André C., Maas, Coen, and Röckmann, Heike

Published
2019

41. Occurrence of an Abscopal Radiation Recall Phenomenon in a Glioblastoma Patient Treated with Nivolumab and Re-Irradiation

Author

Unit Opleiding Dermatologie, MS Medische Oncologie, MS Dermatologie/Allergologie, Pathologie Moleculair, Pathologie Pathologen staf, MS Radiotherapie, Van Seggelen, Wouter O., De Vos, Filip Y., Röckmann, Heike, Van Dijk, Marijke R., Verhoeff, Joost J.C., Unit Opleiding Dermatologie, MS Medische Oncologie, MS Dermatologie/Allergologie, Pathologie Moleculair, Pathologie Pathologen staf, MS Radiotherapie, Van Seggelen, Wouter O., De Vos, Filip Y., Röckmann, Heike, Van Dijk, Marijke R., and Verhoeff, Joost J.C.

Published
2019

44. Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria

Author

van den Elzen, Mignon T, van Os-Medendorp, Harmieke, van den Brink, Imke, van den Hurk, Karin, Kouznetsova, Ouliana I, Lokin, Alexander S H J, Laheij-de Boer, Anna-Marijke, Röckmann, Heike, Bruijnzeel-Koomen, Carla A F M, Knulst, André C, van den Elzen, Mignon T, van Os-Medendorp, Harmieke, van den Brink, Imke, van den Hurk, Karin, Kouznetsova, Ouliana I, Lokin, Alexander S H J, Laheij-de Boer, Anna-Marijke, Röckmann, Heike, Bruijnzeel-Koomen, Carla A F M, and Knulst, André C

Published
2017

45. Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, Afdeling Dermatologie/Allergologie, Arts-assistenten Nucleaire Geneesk., DIGD-Medisch 1, van den Elzen, Mignon T, van Os-Medendorp, Harmieke, van den Brink, Imke, van den Hurk, Karin, Kouznetsova, Ouliana I, Lokin, Alexander S H J, Laheij-de Boer, Anna-Marijke, Röckmann, Heike, Bruijnzeel-Koomen, Carla A F M, Knulst, André C, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, Afdeling Dermatologie/Allergologie, Arts-assistenten Nucleaire Geneesk., DIGD-Medisch 1, van den Elzen, Mignon T, van Os-Medendorp, Harmieke, van den Brink, Imke, van den Hurk, Karin, Kouznetsova, Ouliana I, Lokin, Alexander S H J, Laheij-de Boer, Anna-Marijke, Röckmann, Heike, Bruijnzeel-Koomen, Carla A F M, and Knulst, André C

Published
2017

46. Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria

Author

van den Elzen, Mignon T., primary, van Os-Medendorp, Harmieke, additional, van den Brink, Imke, additional, van den Hurk, Karin, additional, Kouznetsova, Ouliana I., additional, Lokin, Alexander S. H. J., additional, Laheij-de Boer, Anna-Marijke, additional, Röckmann, Heike, additional, Bruijnzeel-Koomen, Carla A. F. M., additional, and Knulst, André C., additional

Published
2017
Full Text
View/download PDF

47. Drug rash with eosinophilia and systemic symptoms caused by the dietary supplement diindolylmethane

Author

Infection & Immunity, MS Dermatologie/Allergologie, Other research (not in main researchprogram), CDL Celdiagnostiek, MS MDL 1, Cancer, Le, Thuy My, Sanders, Cornelus J G, Corput, Lisette van de, van Erpecum, Karel J., Röckmann, Heike, Infection & Immunity, MS Dermatologie/Allergologie, Other research (not in main researchprogram), CDL Celdiagnostiek, MS MDL 1, Cancer, Le, Thuy My, Sanders, Cornelus J G, Corput, Lisette van de, van Erpecum, Karel J., and Röckmann, Heike

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results